{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Change in mutations in tumor tissue at baseline and end of treatment (EOT). EOT tumor biopsies were optional and there were no EOT samples collected.","groups":[{"description":"Patients with a PDGFRA D842V Mutation, any line of treatment","id":"OG000","title":"Patients With a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have received 1 prior line of therapy","id":"OG001","title":"2L Patients Without a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have had 2 or more prior lines of therapy","id":"OG002","title":"3L Patients Without a PDGFRA D842V Mutation"}],"populationDescription":"Patients with pre-and post-treatment tumor biopsies. No patients provided a post-treatment biopsy.","reportingStatus":"POSTED","timeFrame":"Baseline and end of treatment","title":"KIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT","type":"SECONDARY"}